Skip to content
Back to Guavy Wire
Stocks

Bio-Techne Shareholders Approve Merck Acquisition Deal

Instruments
MRK
Share

Bio-Techne Corporation shareholders have given the green light to its acquisition by Merck KGaA, marking a significant step forward for the biotechnology company. The deal, which was approved on September 23, 2026, assigns a cash value of USD 73.00 per share. This approval removes a key shareholder…

The Wire

Read the full article for free.

A free account opens the rest of this article, how it scored, and the full Wire stream. No card required.

No spam. Unsubscribe anytime.

Disclaimer: Guavy is a data and market intelligence provider, not an investment adviser. The information, signals, and market analysis provided by the Guavy API and related services are for informational purposes only and are not intended as financial advice, investment recommendations, or an endorsement of any particular trading strategy. Trading in volatile markets, including cryptocurrency, carries significant risk and may not be suitable for all investors. Past performance is not indicative of future results. Users should consult with a qualified financial professional before making any investment decisions. Guavy makes no guarantee of trading profits or financial returns.

Market sentiment intelligence for apps, funds & agents

Location

729 55 Ave SW
Calgary AB T2V 0G4
Canada

© 2026 Guavy Inc